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Abstract
Sunitinib resistance is a major clinical problem hampering the treatment of  renal cell carcinoma (RCC). Studies on the comprehensive charac-
terisation of  morphological, functional and molecular changes in sunitinib-resistant RCC cells are lacking. The aim of  the current study was 
to develop sunitinib resistance in four human RCC cell lines (786-0, Caki-1, Caki-2 and SN12K1), and to characterise the changed cell biology 
with sunitinib resistance. RCC cells were made resistant by continuous, chronic exposure to 10 µM of  sunitinib over a period of  12 months. 
Cell proliferation, morphology, transmigration, and gene expression for interleukin-6 (IL-6), interleukin-8 (IL-8), vascular endothelial growth 
factor (VEGF), Bcl-2 and Bax were studied. There was no significant difference in growth rate or transmigration between the parental and 
resistant cells. Sunitinib-resistant cells were significantly hypertrophic compared with parental cells as evidenced by increases in the surface 
areas of  the whole cells and the nuclei. IL-6 was significantly increased in all resistant cells. IL-8 was increased in sunitinib-resistant Caki-2 
and SN12K1 cells and decreased in 786-0 without any significant changes in Caki-1. VEGF was increased in resistant Caki-2 and SN12K1 
cells but not in 786-0 and Caki-1. The Bcl2/Bax ratio was increased in Caki-1, Caki-2 and SN12K1 cells but decreased in 786-0 cells. The 
increased IL-6 may contribute to sunitinib resistance either via VEGF-mediated angiogenesis or through shifting of  the Bcl2/Bax balance in 
favour of  anti-apoptosis.
Keywords: angiogenesis; anti-apoptosis; interleukin-6; renal cell carcinoma; sunitinib resistance
Received: 27 May 2018; Accepted after revision: 16 July 2018; Published: 10 August 2018.
Author for correspondence: Christudas Morais, Department of Urology, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, QLD 
4102, Brisbane, Australia. Email: christudas.morais@health.qld.gov.au
How to cite: Kamli H et al. Characterisation of the morphological, functional and molecular changes in sunitinib-resistant renal cell carcinoma 
cells. J Kidney Cancer VHL. 2018;5(3):1–9.
DOI: http://dx.doi.org/10.15586/jkcvhl.2018.106
Copyright: Kamli H et al.
License: This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). http://creativecommons.org/ 
licenses/by/4.0
Introduction
Vascular endothelial growth factor receptor (VEGFR)- 
targeted tyrosine kinase inhibitors (TKIs) have become the 
mainstay of treatment for metastatic renal cell carcinoma 
(RCC). Sunitinib is one of the first-line TKIs (1–5) that tar-
gets multiple receptor tyrosine kinases such as VEGFR-1, 
VEGFR-2 and VEGFR-3; platelet-derived growth factor re-
ceptor alpha (PDGFR)-α and (PDGFR)-β; stem cell growth 
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factor receptor (KIT); fms-related tyrosine kinase 3 (FLT3); 
glial cell line–derived neurotrophic factor receptor (RET); 
and colony-stimulating factor receptor 1 (CSF1R) (6–9). 
Sunitinib targets not only endothelial cells and the endothe-
lial proangiogenic factors (9) but also the tumour cells (8), 
leading to inhibition of angiogenesis and regression of tu-
mours. As with most chemotherapeutics, resistance to suni-
tinib is a concern. About 30% of patients are thought to be 
inherently resistant to sunitinib (10–14) and the remaining 
70% who initially respond will eventually develop acquired 
resistance during the course of the treatment, usually within 
12 months (10–13, 15–17).
Many in vitro studies have attempted to elucidate the mech-
anisms of acquired resistance to sunitinib. Based on current 
knowledge, the mechanisms behind sunitinib resistance can be 
grouped under two major categories: reduced bioavailability 
and activation of alternate angiogenesis pathways. Reduced 
bioavailability is mediated either through the sequestration 
of sunitinib in lysosomes or through ral- interacting protein 
76 (RLIP76) transporters and sphingosine kinase-1 (SK1)-
mediated efflux (18–20). Activation of alternate angiogene-
sis pathway is the result of a myriad of molecules including 
ATX (autotaxin) (21), chemokines (22), Cox-2 (cycloxygen-
ase-2) (23), EMMPRIN (extracellular matrix metalloprotein-
ase inducer) (24), HDM2 (human double minute 2), HDMX 
(human double minute x) (25), IL-8 (26), IL-6 (27, 28), LPA 
(lysophosphatidic acid) (21), MDSC (myeloid-derived sup-
pressor cells) (29), NGAL (neutrophil gelatinase-associated 
lipocalin) (30), PRKX (protein kinase x-linked) (31), PTEN 
(phosphatase and tensin homolog) (32), microRNAs (33) 
and many more emerging molecules and signalling pathways. 
In addition to the molecular changes, sunitinib may induce 
morphologic changes to RCC cells, for example, changes in-
dicative of epithelial–mesenchymal transition (34). Despite 
these, to the best of our knowledge, studies on comprehen-
sive characterisation of the morphological, functional and 
molecular changes in sunitinib-resistant RCC cells are lack-
ing. In the current study, we established four human RCC cell 
lines that are resistant to sunitinib, and characterised their 
morphological, functional and possible molecular mecha-
nisms of sunitinib resistance.
Materials and Methods
Cell culture
The RCC cell lines 786-0, Caki-1 and Caki-2 were obtained 
from American Type Culture Collection (Rockville, MD). 
Another human RCC cell line, SN12K1, was obtained from 
Professor D Nicol, Princess Alexandra Hospital, Brisbane, 
Australia, through his collaborations with Dr IJ Fidler, Can-
cer Research Institute, MD Anderson Cancer Center, Hous-
ton, TX, USA. The RCC cell lines were cultured in DMEM/
F12 (Gibco, Invitrogen, CA, USA) supplemented with fo-
etal bovine serum (10%), penicillin (50 U/ml), streptomycin 
(50 µg/ml) and amphotericin B (0.125 µg/ml) in a humidified 
atmosphere of 5% CO
2
 in air at 37°C. All cell lines were re-
currently tested and determined to be mycoplasma-free.
Development of sunitinib-resistant RCC cell lines
Cells resistant to 10 µM sunitinib were established by expo-
sure to increasing concentrations of sunitinib. In brief, the 
RCC cell lines were treated with varying concentrations of 
sunitinib (0, 1, 5, 10, 20, 50 and 100 µM). While all concen-
trations above 1µM inhibited the growth rate of the RCC cell 
lines, at 10 µM, more than 98% of cells were dead by 72 h, as 
measured by MTT assay. It was assumed that the remaining 
cells were a mix of transient (or tolerant) and stable resistant 
cells. If  this assumption is true, with the passage of time, the 
transient cells are eliminated, and only stably resistant cells 
would eventually grow to confluence. With this assumption, 
these cells were continually maintained in 10 µM sunitinib 
and passaged every 4 days and the cells that eventually grew to 
confluence were developed into stable sunitinib-resistant cells 
over a period of 12 months. At no point during the develop-
ment process were the cells in sunitinib-free medium. Further 
experiments showed that these cells were also resistant to 20 
and 40 µM sunitinib. However, experiments were conducted 
in 10 µM. The results presented are from sunitinib-resistant 
cells that had been in culture for more than 12 months.
Measurement of cell and nuclear size as a marker 
of hypertrophy
The surface area of whole cell and nucleus, as a marker of 
hypertrophy, was analysed as per previous reports (35, 36). 
In brief, parental and resistant cells were seeded and cul-
tured on glass cover slips in 24-well plates at a density of 
4 × 104 cells/ml. After 24 h, the cells were washed in phos-
phate-buffered saline (PBS), fixed for 20 min at room tem-
perature in 4% formaldehyde, stained with haematoxylin and 
eosin as per routine methodology and mounted with DePex 
mounting medium. The cells were viewed under a Nikon 
Eclipse 50i microscope (Nikon Instruments Inc., NY, USA) 
at 200× magnification. Images were captured from four ran-
dom areas of each coverslip using DS-Fi1 colour camera 
(Nikon Australia, Sydney, Australia). Analyses of cell and 
nuclear sizes were performed using NIS Elements Software 
version 2.0 (Nikon Instruments, Melville, NY, USA).
Cell growth assay using MTT
Cells were seeded in 96-well plates (5 × 103 cells/well/100 µl) and 
MTT assay was performed as per previous reports (35–37). After 
pre-determined time periods (24 h–120 h), 5 µl of MTT (Sigma, 
MO, USA), from a 5 mg/ml stock in PBS, were added to each 
well of the culture plates and incubated for 90 min at 37°C in 
a humidified atmosphere of 95% air and 5% CO
2
. The culture 
medium was removed, and the purple crystals formed were 
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dissolved in 100 µl of dimethyl sulfoxide (DMSO). The absor-
bance was read at 570 nm with a background correction of 690 
nm in a Multiscan Go Microplate Reader (Thermo Scientific, 
Waltham, MA, USA). The percentage of cell viability was calcu-
lated relative to the control wells, which were designated as 100%.
Transmigration
Transmigration assay was performed using transwell migra-
tion chambers following the protocol of the supplier (Thermo 
Fisher Scientific Australia Pty Ltd; Cat # NUN140629; 8 µm 
pore size). Briefly, the cells were suspended in serum-free 
DMEM/F12 medium and seeded on the upper compart-
ment of the transwell. Five hundred microlitres of culture 
medium containing 10% FBS were added as chemoattrac-
tant to the bottom chamber. After 24 h, non-migrated cells 
from the upper surface of the membrane were removed using 
a wet cotton swab. The migrated cells on the lower surface 
of the membrane were fixed in 4% formaldehyde, stained 
with toluidine blue (1% in a 1% aqueous solution of borax) 
and mounted with DePex mounting medium. The cells were 
viewed under a 40 × objective and counted from five random 
fields.
Gene expression studies
Total RNA was isolated from cells using PureLink RNA Mini 
Kit as per the manufacturer’s instructions (Life Technologies, 
Carlsbad, CA, USA). After quantifying with Nano drop 
(Thermoscientific, Waltham, MA, USA), cDNA was synthe-
sised using a high capacity cDNA Reverse Transcription Kit 
(Life Technologies). In brief, 1 µg of RNA in reaction mix-
ture (2 µL 10× buffer, 0.8 µL dNTP, 2 µL r-hex, 1 µL enzyme, 
water to 20 µL per reaction) was subjected to the following 
PCR conditions: 25°C for 10 min, 37°C for 60 min, 37°C 
for 60 min, 80°C for 5 min followed by holding at 4°C. The 
cDNA was diluted to 50 µL with 30 µL of RNAse-free water. 
Fully validated TaqMan Gene Expression Assay (Life Tech-
nologies) for Bax (Hs00180269_m1), Bcl2 (Hs00236808_m1), 
IL-6 (Hs00985639_m1), IL-8 (Hs00174103_m1) and VEGFA 
(Hs00900055_m1) was used with the SensiFAST™ Probe 
No-ROX Kit (Bioline, London, UK) in a LightCycler 480 
(Roche Applied Science, Penzberg, Germany) to determine 
relative gene expression by the comparative Ct method. TBP 
(TATA box binding protein; Hs00427620_m1) was used as an 
internal control and for normalisation (35–37).
Statistical analyses
The results were expressed as mean ± standard deviation of 
mean. Comparisons between groups were analysed using 
analysis of variance (ANOVA) with Tukey’s post hoc test or 
Student’s t-test, where appropriate. Analyses were performed 
using Graphpad Instat software (San Diego, CA, USA). A 
p-value of <0.05 was considered significant. The results pre-
sented are representatives of three independent experiments.
Results
Morphological changes
Morphometric studies showed significant hypertrophy in suni-
tinib-resistant cell lines, as evidenced by increases in the surface 
areas of the whole cells and the nuclei (Figure 1). Representative 
H&E stained cells from each group are shown in Figure 2. While 
all cell types were hypertrophic, considerable morphologic het-
erogeneity could be observed in the resistant cells. In particular, 
786-0 showed spindle morphology, whereas the SN12K1 cells 
displayed multi-lobulated nuclei. Observation of live cells under 
phase contrast microscope further confirmed hypertrophic and 
heterogenic features of resistant cells (Figure 3).
Figure 1. Sunitinib-resistant cells are hypertrophic. RCC cell lines that are resistant to 10 µM of  sunitinib showed signifi-
cant increases in the surface areas of  the whole cells and the nuclei. Results are presented as percentage of  the control group. 
**P < 0.01 and ***P < 0.001.
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Growth and transmigration
Although the resistant cells showed a slightly decreased growth 
rate, at no point in time during the course of the study was this 
difference statistically significant (Figure 4). Similarly, there 
was no statistically significant difference in transmigration 
between the parental and sunitinib-resistant cells (Figure 5). 
Whether this lack of difference is the reflection of increased 
size of the sunitinib-resistant cells preventing them from mi-
grating or actual decrease in transmigration is not clear.
Gene expression
To investigate the possible mechanisms behind resistance, we 
studied the expression patterns of the proangiogenic factors 
IL-6, IL-8 and VEGF, and apoptosis-regulatory molecules 
Bcl-2 and Bax. In all resistant cells, IL-6 was the only common 
molecule that was overexpressed (Figure 6). IL-8 was increased 
in Caki-2 and SN12K1 cells and decreased in 786-0. No sig-
nificant change was observed in Caki-1. Interestingly, VEGF 
was increased in resistant Caki-2 and SN12K1 cells, without 
Figure 2. Morphological heterogeneity and nuclear atypia in sunitinib-resistant cells. Representative H&E images showing 
increased cell and nuclear size in resistant cells. The 786-0 appeared spindle-shaped whereas the SN12K1 showed multi-lobular 
nucleus or nuclear blebs.
Figure 3. Phase contrast microscopy of live cells showing hypertrophy of sunitinib-resistant cells. Representative phase contrast 
microscopy further confirms the hypertrophic nature of sunitinib-resistant cells.
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Figure 4. Growth rate showed no significant difference between control and sunitinib-resistant cells. In general, resistant cells 
showed a slightly decreased growth rate but this was not statistically significant. Results are expressed as percentage of control.
Figure 5. Lack of difference in transmigration between control and sunitinib-resistant cells. After 24 h of transmigration, 
in response to 10% FBS as a chemoattractant, no statistically significant difference was observed between the parental and 
 sunitinib-resistant cells. Results are expressed as percentage of control.
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any significant changes in 786-0 and Caki-1 ( Figure 7). The 
Bcl2/Bax ratio was increased in Caki-1, Caki-2 and SN12K1 
cells but decreased in 786-0 cells (Figure 7).
Discussion
There is no universal consensus or guidelines on how drug- 
resistant cells should be developed in vitro. The underlying 
principle is to develop cells that are resistant to concentrations 
that would otherwise kill the parental cells. There are many 
methods, each with its own advantages and disadvantages, 
and the choice is often at the discretion of the investigators. 
Furthermore, there is no agreement on the terminology on 
whether it is drug tolerance or resistance, which also varies 
from investigator to investigator. In our procedure, we as-
sumed that the cells that do not die in response to a particular 
concentration are indeed resistant to that concentration and 
decided to develop these cells as the resistant cells. We were 
seeking for the highest concentration of sunitinib that would 
kill most of the cells, but not all. In this regard, 10 µM suni-
tinib killed most of the cells (approximately 98%) within 72 h 
and the remaining 2% of cells were developed to sunitinib re-
sistance. At this stage, the most common practice is to provide 
a drug holiday period in which the drug is removed from the 
culture, and the cells are allowed to recover and are rechal-
lenged again (38, 39). Thus, cells undergo multiple cycles of 
drug rechallenge and drug holiday period before being devel-
oped into resistant cells. In our method, the cells were never 
without drugs and it took approximately 12 months to de-
velop stable sunitinib-resistant cells. Although they were de-
veloped with 10 µM sunitinib, they were eventually resistant 
to up to 40 µM sunitinib. The experiments were performed 
with 10 µM sunitinib because, translationally, dose escalation 
is not a common practice and could cause much toxicity.
Morphologically, all resistant cell lines showed hypertro-
phy. Hatakeyama et  al. (40) reported similar findings for 
Figure 6. IL-6 is increased in all resistant cells. IL-6 was the common molecule that was increased in all sunitinib-resistant cells. 
Regarding IL-8, heterogeneity in expression was observed. ***P < 0.001.
Figure 7. Differential expression of proangiogenic and apoptosis-regulatory genes in resistant cells. There was an increased 
expression of the proangiogenic gene VEGF in Caki-2 and SN12K1 cells and an increased Bcl2/Bax ratio in Caki-1, Caki-2 and 
SN12K1 cells. *P < 0.05, **P < 0.01 and ***P < 0.001.
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786-0 cells in which the nuclei of  sunitinib-resistant cells were 
increased  threefold when compared to parental cell lines; 
however, the size of  the whole cells was not reported in this 
study. The relevance of  hypertrophy in sunitinib- resistant 
cells is not clear. It could be an adaptation of  the cells to re-
distribute the drug so that the overall intracellular drug con-
centration is less thus somehow “diluting” the effect of  the 
drug. However, the flaw in this argument is that it could also 
work the other way around, for example, more surface area 
is present to absorb more drug. The intracellular concentra-
tion of  sunitinib in these cells is worth pursuing.  Nuclear 
atypia, including larger size and multilobulation (or nuclear 
bleb formation) as seen in SN12K1 cells, is not uncommon 
in laminopathies and cancers, and it is associated with high-
grade cancers (41).
Despite larger nucleus or nuclear atypia, the surprising 
finding was the lack of  functional aspects in resistant cells 
that are often considered as “aggressive” in cancer biology, 
as they did not show any significant difference when com-
pared with the parental cells. For example, Burtz et al. (42), 
in an in vivo experimental model, reported that sunitinib-re-
sistant renal tumours exhibited aggressive behaviour such 
as sarcomatoid differentiation, extensive vascular and local 
invasion, and liver and lung metastases. In our study, resis-
tant cells did not show any significant changes in growth 
or transmigration when compared with parental cells. Our 
results on growth are in agreement with the report of  Sakai 
et al. (43) who developed ACHN cells that are resistant to 
10  µM sunitinib. Taken together, the functional data ap-
pear to suggest that resistance is not necessarily a concern 
in terms of  aggressiveness. Perhaps, these are simply non- 
responsive cells without any added aggression. This pro-
posal warrants further exploration.
RCC is a highly heterogeneous disease. While no signifi-
cant heterogeneity could be observed on the functional as-
pects, it was obvious in the molecular signature. IL-6 was 
the only molecule that was increased in all cells. As IL-6 is 
a regulator of  VEGF, with the consensus on a mechanism 
of  angiogenesis restoration or neovascularisation (22, 39, 
44), the expression of  VEGF was assessed. Interestingly, 
only two cell lines (Caki-2 and SN12K1) had a significant 
increase in VEGF mRNA. Thus, VEGF, or angiogen-
esis, is not necessarily the sole mediator of  resistance. To 
find alternative mechanisms, we explored molecules that 
regulate apoptosis because apoptosis has been reported to 
be a mechanism of  cell death in RCC in response to suni-
tinib treatment (45, 46). The results showed that the equi-
librium was shifted in favour of  the anti-apoptotic molecule 
Bcl2. Thus, it is not only angiogenesis but also resistance 
to apoptosis that appear to play a role. To the best of  our 
knowledge, this is the first experimental evidence for the 
role of  anti-apoptosis mechanisms in sunitinib resistance 
of  RCC.
Conclusion
The question arises regarding the best way to combat resis-
tance. One way is to combine other antiangiogenic agents 
with sunitinib. Although clinical trials combining bevaci-
zumab and sunitinib showed anti-tumour activity, toxicity 
precludes further clinical development (47–49). Bcl2 inhibi-
tion has long been tried but has not progressed beyond exper-
imental stage (50). Inhibition of IL-6 could be a promising 
way to overcome drug resistance. In this regard, a recent 
study showed the beneficial effect of IL-6 receptor inhibition 
to overcome sunitinib resistance (28). Combination of suni-
tinib with the ILR-6 inhibitor tocilizumab to overcome suni-
tinib warrants further research.
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